These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
121 related articles for article (PubMed ID: 16684432)
1. Are generic formulations of carvedilol of inferior pharmaceutical quality compared with the branded formulation? Smith JC; Tarocco G; Merazzi F; Salzmann U Curr Med Res Opin; 2006 Apr; 22(4):709-20. PubMed ID: 16684432 [TBL] [Abstract][Full Text] [Related]
2. Pharmaceutical quality of generic isotretinoin products, compared with Roaccutane. Taylor PW; Keenan MH Curr Med Res Opin; 2006 Mar; 22(3):603-15. PubMed ID: 16574043 [TBL] [Abstract][Full Text] [Related]
3. Pharmaceutical quality of seven generic Levodopa/Benserazide products compared with original Madopar® / Prolopa®. Gasser UE; Fischer A; Timmermans JP; Arnet I BMC Pharmacol Toxicol; 2013 Apr; 14():24. PubMed ID: 23617953 [TBL] [Abstract][Full Text] [Related]
4. Bioequivalence study of two different tablet formulations of carvedilol in healthy volunteers. Portolés A; Filipe A; Almeida S; Terleira A; Vallée F; Vargas E Arzneimittelforschung; 2005; 55(4):212-7. PubMed ID: 15901044 [TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetic profile of controlled-release carvedilol in patients with left ventricular dysfunction associated with chronic heart failure or after myocardial infarction. Packer M; Lukas MA; Tenero DM; Baidoo CA; Greenberg BH; Am J Cardiol; 2006 Oct; 98(7A):39L-45L. PubMed ID: 17023231 [TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic and pharmacodynamic comparison of controlled-release carvedilol and immediate-release carvedilol at steady state in patients with hypertension. Henderson LS; Tenero DM; Baidoo CA; Campanile AM; Harter AH; Boyle D; Danoff TM Am J Cardiol; 2006 Oct; 98(7A):17L-26L. PubMed ID: 17023228 [TBL] [Abstract][Full Text] [Related]
7. Integration of in vitro biorelevant dissolution and in silico PBPK model of carvedilol to predict bioequivalence of oral drug products. Ibarra M; Valiante C; Sopeña P; Schiavo A; Lorier M; Vázquez M; Fagiolino P Eur J Pharm Sci; 2018 Jun; 118():176-182. PubMed ID: 29605455 [TBL] [Abstract][Full Text] [Related]
8. Studies on formulation development of mouth dissolving tablets of Carvedilol. Pokharkar V; Dhar S; Mandpe L Hindustan Antibiot Bull; 2007 Feb-2008 Nov; 49-50(1-4):21-8. PubMed ID: 19957540 [TBL] [Abstract][Full Text] [Related]
9. Quantification of carvedilol in human plasma by high-performance liquid chromatography coupled to electrospray tandem mass spectrometry: application to bioequivalence study. do Carmo Borges NC; Mendes GD; de Oliveira Silva D; Marcondes Rezende V; Barrientos-Astigarraga RE; De Nucci G J Chromatogr B Analyt Technol Biomed Life Sci; 2005 Aug; 822(1-2):253-62. PubMed ID: 16005691 [TBL] [Abstract][Full Text] [Related]
10. Pharmaceutical quality of nine generic orlistat products compared with Xenical(r). Taylor PW; Arnet I; Fischer A; Simpson IN Obes Facts; 2010 Aug; 3(4):231-7. PubMed ID: 20823686 [TBL] [Abstract][Full Text] [Related]
11. [Trends in the quality evaluation of generic products and bioequivalence guidelines]. Yomota C Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho Hokoku; 2012; (130):1-12. PubMed ID: 23243982 [TBL] [Abstract][Full Text] [Related]
12. Role of carvedilol controlled-release in cardiovascular disease. Fonarow GC Expert Rev Cardiovasc Ther; 2009 May; 7(5):483-98. PubMed ID: 19419256 [TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetic properties of a new controlled-release formulation of carvedilol. Tenero DM; Henderson LS; Baidoo CA; Harter AH; Campanile AM; Danoff TM; Boyle D Am J Cardiol; 2006 Oct; 98(7A):5L-16L. PubMed ID: 17023227 [TBL] [Abstract][Full Text] [Related]
14. The early anti-oxidant effect of carvedilol predicts the clinical course in congestive heart failure patients. Goldhammer E; Maor I; Shnitzer S; Lanir A; Abinader EG J Cardiovasc Med (Hagerstown); 2007 Jun; 8(6):453-6. PubMed ID: 17502762 [TBL] [Abstract][Full Text] [Related]
15. Development of a pharmacokinetic/pharmacodynamic model for carvedilol to predict beta1-blockade in patients with congestive heart failure. Tenero DM; Henderson LS; Campanile AM; Baidoo CA; Boyle D Am J Cardiol; 2006 Oct; 98(7A):27L-31L. PubMed ID: 17023229 [TBL] [Abstract][Full Text] [Related]
17. Carvedilol: use in chronic heart failure. Doughty RN; White HD Expert Rev Cardiovasc Ther; 2007 Jan; 5(1):21-31. PubMed ID: 17187454 [TBL] [Abstract][Full Text] [Related]
18. Differences between beta-blockers in patients with chronic heart failure and chronic obstructive pulmonary disease: a randomized crossover trial. Jabbour A; Macdonald PS; Keogh AM; Kotlyar E; Mellemkjaer S; Coleman CF; Elsik M; Krum H; Hayward CS J Am Coll Cardiol; 2010 Apr; 55(17):1780-7. PubMed ID: 20413026 [TBL] [Abstract][Full Text] [Related]
19. Effects of branded versus generic terazosin hydrochloride in adults with benign prostatic hyperplasia: a randomized, open-label, crossover study in Taiwan. Tsai YS; Lan SK; Ou JH; Tzai TS Clin Ther; 2007 Apr; 29(4):670-82. PubMed ID: 17617290 [TBL] [Abstract][Full Text] [Related]
20. Mucoadhesive bilayer buccal tablet of carvedilol-loaded chitosan microspheres: in vitro, pharmacokinetic and pharmacodynamic investigations. Yedurkar P; Dhiman MK; Petkar K; Sawant K J Microencapsul; 2012; 29(2):126-37. PubMed ID: 22047549 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]